Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:ALOG's Cash-to-Debt is ranked higher than
97% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.86 vs. NAS:ALOG: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ALOG' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.98  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.86
NAS:ALOG's Equity-to-Asset is ranked higher than
89% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:ALOG: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ALOG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.71  Med: 0.84 Max: 0.88
Current: 0.86
0.71
0.88
Interest Coverage No Debt
NAS:ALOG's Interest Coverage is ranked higher than
97% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.70 vs. NAS:ALOG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ALOG' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 7
Altman Z-Score: 9.02
Beneish M-Score: -2.73
WACC vs ROIC
9.58%
6.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 6.77
NAS:ALOG's Operating Margin % is ranked higher than
60% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. NAS:ALOG: 6.77 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ALOG' s Operating Margin % Range Over the Past 10 Years
Min: -1.06  Med: 5.38 Max: 8.24
Current: 6.77
-1.06
8.24
Net Margin % 4.58
NAS:ALOG's Net Margin % is ranked higher than
61% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. NAS:ALOG: 4.58 )
Ranked among companies with meaningful Net Margin % only.
NAS:ALOG' s Net Margin % Range Over the Past 10 Years
Min: 0.94  Med: 5.08 Max: 8.34
Current: 4.58
0.94
8.34
ROE % 4.48
NAS:ALOG's ROE % is ranked higher than
58% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.21 vs. NAS:ALOG: 4.48 )
Ranked among companies with meaningful ROE % only.
NAS:ALOG' s ROE % Range Over the Past 10 Years
Min: 0.9  Med: 5 Max: 9.9
Current: 4.48
0.9
9.9
ROA % 3.74
NAS:ALOG's ROA % is ranked higher than
64% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. NAS:ALOG: 3.74 )
Ranked among companies with meaningful ROA % only.
NAS:ALOG' s ROA % Range Over the Past 10 Years
Min: 0.76  Med: 4.19 Max: 7.98
Current: 3.74
0.76
7.98
ROC (Joel Greenblatt) % 12.23
NAS:ALOG's ROC (Joel Greenblatt) % is ranked higher than
57% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. NAS:ALOG: 12.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ALOG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2.21  Med: 11.09 Max: 18.74
Current: 12.23
-2.21
18.74
3-Year Revenue Growth Rate -2.70
NAS:ALOG's 3-Year Revenue Growth Rate is ranked lower than
68% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. NAS:ALOG: -2.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ALOG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.4  Med: 3.8 Max: 15.9
Current: -2.7
-10.4
15.9
3-Year EBITDA Growth Rate -8.50
NAS:ALOG's 3-Year EBITDA Growth Rate is ranked lower than
68% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. NAS:ALOG: -8.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ALOG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.1  Med: -2.2 Max: 62.7
Current: -8.5
-41.1
62.7
3-Year EPS without NRI Growth Rate -27.10
NAS:ALOG's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. NAS:ALOG: -27.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ALOG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56  Med: -8 Max: 127.6
Current: -27.1
-56
127.6
GuruFocus has detected 1 Warning Sign with Analogic Corp $NAS:ALOG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ALOG's 10-Y Financials

Financials (Next Earnings Date: 2017-06-06 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ALOG Guru Trades in Q1 2016

Joel Greenblatt 35,680 sh (New)
NWQ Managers 544,777 sh (+7.09%)
Chuck Royce 565,701 sh (+4.23%)
Mariko Gordon 578,814 sh (+3.75%)
Jim Simons 19,800 sh (-8.98%)
Richard Snow 139,590 sh (-24.46%)
» More
Q2 2016

ALOG Guru Trades in Q2 2016

Joel Greenblatt 92,284 sh (+158.64%)
Chuck Royce 580,101 sh (+2.55%)
NWQ Managers 547,037 sh (+0.41%)
Jim Simons Sold Out
Mariko Gordon 567,408 sh (-1.97%)
Richard Snow 128,985 sh (-7.60%)
» More
Q3 2016

ALOG Guru Trades in Q3 2016

Chuck Royce 588,851 sh (+1.51%)
NWQ Managers 517,550 sh (-5.39%)
Richard Snow 97,775 sh (-24.20%)
Mariko Gordon 416,175 sh (-26.65%)
Joel Greenblatt 55,449 sh (-39.91%)
» More
Q4 2016

ALOG Guru Trades in Q4 2016

Chuck Royce 587,384 sh (-0.25%)
NWQ Managers 507,905 sh (-1.86%)
Mariko Gordon 275,769 sh (-33.74%)
Richard Snow 40,558 sh (-58.52%)
Joel Greenblatt 6,227 sh (-88.77%)
» More
» Details

Insider Trades

Latest Guru Trades with ALOG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 8071
Compare:NAS:KANG, NAS:GHDX, NAS:BEAT, NAS:ABAX, NAS:MEDP, NAS:VREX, NAS:FMI, NAS:QDEL, NAS:AXDX, NAS:HSKA, NAS:NEO, NAS:VIVO, NAS:MYGN, NYSE:ARA, NAS:NRCIA, NAS:NTRA, NAS:LNTH, NAS:NVDQ, NYSE:NVTA, NAS:OXFD » details
Traded in other countries:AJM.Germany,
Analogic Corp is a technology company that designs and manufactures medical imaging ultrasound and security systems and subsystems sold to original equipment manufacturers, or OEMs, and end users in the healthcare and airport security markets.

Analogic Corporation was incorporated in the Commonwealth of Massachusetts in November 1967. The company is a technology company that designs and manufactures medical imaging and security systems and subsystems sold to original equipment manufacturers, or OEMs, and end users mainly in the healthcare and airport security markets. The Company's operating segments are Ultrasound, Medical Imaging, and Security and Detection. The Ultrasound segment provides ultrasound guidance systems for the urology and surgery markets and is expanding into point of care areas such as anesthesia and emergency medicine. The Medical Imaging segment provides critical enabling medical imaging systems and subsystems for computed tomography, or CT, magnetic resonance imaging, or MRI and high-resolution digital mammography systems. The Security and Detection segment designs and manufactures automated threat detection systems for aviation baggage inspection applications utilizing CT technology. Its geographical areas include United states, Japan, Germany, Netherlands and others.

Ratios

vs
industry
vs
history
PE Ratio 38.93
ALOG's PE Ratio is ranked lower than
59% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.02 vs. ALOG: 38.93 )
Ranked among companies with meaningful PE Ratio only.
ALOG' s PE Ratio Range Over the Past 10 Years
Min: 16.49  Med: 33.25 Max: 148.85
Current: 38.93
16.49
148.85
PE Ratio without NRI 38.93
ALOG's PE Ratio without NRI is ranked lower than
60% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. ALOG: 38.93 )
Ranked among companies with meaningful PE Ratio without NRI only.
ALOG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.99  Med: 34.39 Max: 178.18
Current: 38.93
17.99
178.18
Price-to-Owner-Earnings 40.05
ALOG's Price-to-Owner-Earnings is ranked lower than
66% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.06 vs. ALOG: 40.05 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALOG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.84  Med: 54.65 Max: 839.04
Current: 40.05
12.84
839.04
PB Ratio 1.69
ALOG's PB Ratio is ranked higher than
84% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.55 vs. ALOG: 1.69 )
Ranked among companies with meaningful PB Ratio only.
ALOG' s PB Ratio Range Over the Past 10 Years
Min: 0.82  Med: 1.84 Max: 2.53
Current: 1.69
0.82
2.53
PS Ratio 1.79
ALOG's PS Ratio is ranked higher than
70% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. ALOG: 1.79 )
Ranked among companies with meaningful PS Ratio only.
ALOG' s PS Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.8 Max: 3.09
Current: 1.79
0.78
3.09
Price-to-Free-Cash-Flow 22.76
ALOG's Price-to-Free-Cash-Flow is ranked lower than
52% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.34 vs. ALOG: 22.76 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALOG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.87  Med: 33.32 Max: 169.1
Current: 22.76
13.87
169.1
Price-to-Operating-Cash-Flow 16.82
ALOG's Price-to-Operating-Cash-Flow is ranked higher than
51% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.21 vs. ALOG: 16.82 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALOG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.02  Med: 21.57 Max: 81.55
Current: 16.82
9.02
81.55
EV-to-EBIT 21.66
ALOG's EV-to-EBIT is ranked higher than
50% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. ALOG: 21.66 )
Ranked among companies with meaningful EV-to-EBIT only.
ALOG' s EV-to-EBIT Range Over the Past 10 Years
Min: -121.6  Med: 24.7 Max: 388.6
Current: 21.66
-121.6
388.6
EV-to-EBITDA 12.75
ALOG's EV-to-EBITDA is ranked higher than
63% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.84 vs. ALOG: 12.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALOG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.9  Med: 15.1 Max: 48.4
Current: 12.75
5.9
48.4
PEG Ratio 11.71
ALOG's PEG Ratio is ranked lower than
89% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. ALOG: 11.71 )
Ranked among companies with meaningful PEG Ratio only.
ALOG' s PEG Ratio Range Over the Past 10 Years
Min: 0.79  Med: 2.89 Max: 356.36
Current: 11.71
0.79
356.36
Shiller PE Ratio 35.66
ALOG's Shiller PE Ratio is ranked higher than
60% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.56 vs. ALOG: 35.66 )
Ranked among companies with meaningful Shiller PE Ratio only.
ALOG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.43  Med: 36.69 Max: 53.09
Current: 35.66
15.43
53.09
Current Ratio 5.65
ALOG's Current Ratio is ranked higher than
84% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. ALOG: 5.65 )
Ranked among companies with meaningful Current Ratio only.
ALOG' s Current Ratio Range Over the Past 10 Years
Min: 2.82  Med: 5.03 Max: 7.99
Current: 5.65
2.82
7.99
Quick Ratio 3.63
ALOG's Quick Ratio is ranked higher than
72% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. ALOG: 3.63 )
Ranked among companies with meaningful Quick Ratio only.
ALOG' s Quick Ratio Range Over the Past 10 Years
Min: 2.13  Med: 3.62 Max: 6.15
Current: 3.63
2.13
6.15
Days Inventory 185.07
ALOG's Days Inventory is ranked lower than
86% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.88 vs. ALOG: 185.07 )
Ranked among companies with meaningful Days Inventory only.
ALOG' s Days Inventory Range Over the Past 10 Years
Min: 92.53  Med: 118.65 Max: 185.07
Current: 185.07
92.53
185.07
Days Sales Outstanding 64.45
ALOG's Days Sales Outstanding is ranked lower than
54% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 61.18 vs. ALOG: 64.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALOG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.76  Med: 68.08 Max: 80.63
Current: 64.45
58.76
80.63
Days Payable 37.71
ALOG's Days Payable is ranked lower than
64% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. ALOG: 37.71 )
Ranked among companies with meaningful Days Payable only.
ALOG' s Days Payable Range Over the Past 10 Years
Min: 29.72  Med: 36.48 Max: 45.64
Current: 37.71
29.72
45.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.54
ALOG's Dividend Yield % is ranked lower than
77% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. ALOG: 0.54 )
Ranked among companies with meaningful Dividend Yield % only.
ALOG' s Dividend Yield % Range Over the Past 10 Years
Min: 0.41  Med: 0.61 Max: 1.6
Current: 0.54
0.41
1.6
Dividend Payout Ratio 0.21
ALOG's Dividend Payout Ratio is ranked higher than
65% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.25 vs. ALOG: 0.21 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ALOG' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.26 Max: 1.38
Current: 0.21
0.12
1.38
Forward Dividend Yield % 0.54
ALOG's Forward Dividend Yield % is ranked lower than
81% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. ALOG: 0.54 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.54
ALOG's 5-Year Yield-on-Cost % is ranked lower than
83% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. ALOG: 0.54 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALOG' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.41  Med: 0.61 Max: 1.6
Current: 0.54
0.41
1.6
3-Year Average Share Buyback Ratio -0.40
ALOG's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. ALOG: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALOG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.6  Med: -0.4 Max: 2.8
Current: -0.4
-1.6
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 13.68
ALOG's Price-to-Net-Cash is ranked lower than
60% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.00 vs. ALOG: 13.68 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ALOG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.17  Med: 8.26 Max: 148.14
Current: 13.68
3.17
148.14
Price-to-Net-Current-Asset-Value 2.90
ALOG's Price-to-Net-Current-Asset-Value is ranked higher than
84% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.22 vs. ALOG: 2.90 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALOG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.28  Med: 2.58 Max: 4.77
Current: 2.9
1.28
4.77
Price-to-Tangible-Book 2.09
ALOG's Price-to-Tangible-Book is ranked higher than
82% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.72 vs. ALOG: 2.09 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALOG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.93  Med: 1.91 Max: 3.17
Current: 2.09
0.93
3.17
Price-to-Intrinsic-Value-Projected-FCF 1.28
ALOG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
76% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ALOG: 1.28 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALOG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.8  Med: 1.39 Max: 2.06
Current: 1.28
0.8
2.06
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.89
ALOG's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
63% of the 16 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.82 vs. ALOG: 1.89 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.99
ALOG's Price-to-Median-PS-Value is ranked higher than
51% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. ALOG: 0.99 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALOG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 0.98 Max: 1.51
Current: 0.99
0.43
1.51
Price-to-Graham-Number 1.90
ALOG's Price-to-Graham-Number is ranked higher than
68% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.91 vs. ALOG: 1.90 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ALOG' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.99  Med: 1.68 Max: 11.2
Current: 1.9
0.99
11.2
Earnings Yield (Greenblatt) % 4.62
ALOG's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.78 vs. ALOG: 4.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALOG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 4 Max: 8.3
Current: 4.62
0.3
8.3
Forward Rate of Return (Yacktman) % 3.55
ALOG's Forward Rate of Return (Yacktman) % is ranked lower than
60% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. ALOG: 3.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALOG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -20.7  Med: 6.2 Max: 33.9
Current: 3.55
-20.7
33.9

More Statistics

Revenue (TTM) (Mil) $518.7
EPS (TTM) $ 1.88
Beta0.94
Short Percentage of Float6.90%
52-Week Range $72.50 - 95.85
Shares Outstanding (Mil)12.49

Analyst Estimate

Jul17 Jul18
Revenue (Mil $) 533 575
EPS ($) 4.01 4.65
EPS without NRI ($) 4.01 4.65
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ALOG

Headlines

Articles On GuruFocus.com
Mariko Gordon Sells Stake in Dealertrack Technologies Dec 02 2015 
Mariko Gordon Uses Her Magic Touch and Acquires Holdings in Two Companies Nov 23 2015 
Could These Science Stocks Provide Big Gains? Mar 11 2012 
Weekly Top Insider Buys: Health Care REIT Inc., Human Genome Sciences Inc., Conseco Inc., Universal Jan 02 2010 
Analogic Corp. Reports Operating Results (10-K) Sep 29 2009 
Analogic Corp. (ALOG) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
Analogic to Present at the 16th Annual Needham Healthcare Conference Mar 23 2017
BK Ultrasound, Powered by Analogic, Introduces bkFusion at EAU 2017 Mar 23 2017
BK Ultrasound, Powered by Analogic, Introduces bkFusion at EAU 2017 Mar 23 2017
Analogic Corp. :ALOG-US: Earnings Analysis: Q2, 2017 By the Numbers : March 22, 2017 Mar 22 2017
ANALOGIC CORP Financials Mar 16 2017
ANALOGIC CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Mar 15 2017
ANALOGIC CORP Files SEC form 10-Q, Quarterly Report Mar 13 2017
Five ESG Stocks Poised For Big Turnarounds Mar 13 2017
Analogic to Launch Breakthrough Checkpoint Security Screening System for European Aviation Market at... Mar 08 2017
Analogic to Launch Breakthrough Checkpoint Security Screening System for European Aviation Market at... Mar 08 2017
Edited Transcript of ALOG earnings conference call or presentation 6-Mar-17 10:00pm GMT Mar 06 2017
ANALOGIC CORP Files SEC form 8-K, Results of Operations and Financial Condition, Costs Associated... Mar 06 2017
Analogic posts 2Q profit Mar 06 2017
Analogic posts 2Q profit Mar 06 2017
Analogic Announces Results for the Second Quarter ended January 31, 2017 and Declares Quarterly Cash... Mar 06 2017
Q2 2017 Analogic Corp Earnings Release - After Market Close Mar 06 2017
Analogic Announces Timing for Second Quarter 2017 Earnings Conference Call and Webcast Feb 21 2017
ANALOGIC CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Jan 20 2017
Analogic Corporation to Webcast Annual Stockholders’ Meeting Jan 12 2017
ETFs with exposure to Analogic Corp. : January 11, 2017 Jan 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)